Sánchez Peralta, A MOliveras-López, M JPérez González, RMartínez Martínez, FLópez-García de la Serrana, H2013-03-042013-03-042012-03Sánchez Peralta AM, Oliveras-López MJ, Pérez González R, Martínez Martínez F, López-García de la Serrana H. Prevalence of diabetes in a cancer population in a Malaga hospital. Nutr Hosp; 27(2):456-620212-1611http://hdl.handle.net/10668/796Journal Article;Introducción: Existen múltiples factores de riesgo para que una célula degenere en crecimiento indiferenciado o cáncer. Entre otros factores se ha observado que la obesidad, el sedentarismo y la diabetes aumentan este riesgo. La insulina es un factor de crecimiento que promueve la diferenciación celular. Objetivos: El objetivo de nuestro estudio es observar la glucemia basal en una población con cáncer y comparar con una población control. Métodos: Estudiamos la presencia de diabetes mellitus (DM) y de glucosa alterada en ayunas (GAA) en 374 pacientes de distintos tipos de cáncer mediante sus historiales observando la glucemia basal del ingreso antes de su tratamiento. Comparamos con la glucemia basal en población normal por rangos de edad y sexo. Resultados y discusión: La prevalencia de diabetes en los pacientes con cáncer fue de 32,35%. Comparación por sexo y rangos de edad: observamos que entre 45-54 años, DM: 40,91% en hombres cancerosos versus (vs) 14.5% en hombres control (p = 0,005). Entre 55-64 años, GAA: 23,08% en mujeres cancerosas vs 5,9% en mujeres control (p = 0001). Entre 65-74 años, DM: 47,13% en hombres cancerosos vs 25,4% en hombres control (p = 0,000), y GAA: 23,81% en mujeres cancerosas vs 9,5% en mujeres control (p = 0,019). Encontramos una mayor prevalencia de diabetes en unos tipos específicos de cáncer más que en otros, como por ejemplo en el cáncer de próstata (p < 0,005). Así mismo observamos que los hombres tienen una mayor prevalencia de diabetes o un menor control de la enfermedad que las mujeres en nuestra muestra de casos de cáncer. Conclusiones: Recomendamos un diagnóstico sistemático de diabetes en los pacientes con cáncer mediante test de tolerancia oral de glucosa (OGTT) y su conveniente tratamiento. Es posible que la diabetes, o el tener disminuida la actividad insulínica, sea un factor más de riesgo para el cáncer.BACKGROUND There are multiple risk factors for cancer, including obesity, sedentary lifestyle, diabetes (DM). Hormon Insulin is a growth factor that promotes cellular differentiation. AIMS The aim of our study is to observe impaired glycaemia in cancer population compared with control. METHODS We studied the prevalence of diabetes (DM) and impaired fasting glycaemia (IFG) in 374 patients with different types of cancer before treatment, by medical records in a Malaga hospital (Spain). We compared the prevalence of basal hyperglycaemia in these patients with general population, within an age range and by gender. RESULTS AND DISCUSSION The prevalence of diabetes was 32.35% in our cancer patients. The comparison depends of age range, and by gender prevalence was: 45-54 years, DM: 40.91% in men cases, versus (vs.) 14.5% in men control (p = 0.005). 55-64 years, IFG: 23.08% in women cases, vs. 5.9% in women control (p = 0.001). 65-74 years, DM: 47.13% in men cases, vs. 25.4% in men control (p = 0.000), and IFG: 23.81% in women cases, vs. 9.5% in women control (p = 0.019). We found a higher prevalence of diabetes in specific types of cancer such as prostate (p < 0.005). Moreover, men had a higher prevalence of diabetes or less diabetes control than women in our cancer sample. CONCLUSIONS We recommend an OGTT (oral glucose tolerance test) for better diagnosis of possible DM in patients with cancer, and an appropriate treatment. It may be an independent risk factor for cancer to have decreased insulin activity, or DM.enDiabetesOncologyOncologíaMedical Subject Headings::Named Groups::Persons::Age Groups::AdultMedical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Age FactorsMedical Subject Headings::Named Groups::Persons::Age Groups::Adult::AgedMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::AnthropometryMedical Subject Headings::Named Groups::Persons::Age Groups::AdultMedical Subject Headings::Named Groups::Persons::Age Groups::ChildMedical Subject Headings::Named Groups::Persons::Age Groups::Child::Child, PreschoolMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional StudiesMedical Subject Headings::Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes ComplicationsMedical Subject Headings::Diseases::Endocrine System Diseases::Diabetes MellitusMedical Subject Headings::Check Tags::FemaleMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Endocrine::Glucose Tolerance TestMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Named Groups::Persons::Age Groups::InfantMedical Subject Headings::Named Groups::Persons::Patients::InpatientsMedical Subject Headings::Check Tags::MaleMedical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle AgedMedical Subject Headings::Diseases::NeoplasmsMedical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Causality::Risk FactorsMedical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Sex FactorsMedical Subject Headings::Geographicals::Geographic Locations::Europe::SpainMedical Subject Headings::Named Groups::Persons::Age Groups::Adult::Young AdultMedical Subject Headings::Named Groups::Persons::Age Groups::AdolescentMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathological Conditions, Anatomical::HypertrophyMedical Subject Headings::Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Pancreatic Hormones::Insulins::Proinsulin::Insulinresearch article22732968open access10.1590/S0212-161120120002000161699-5198